Glycyrrhizic acid suppresses Cox-2-mediated anti-inflammatory responses during Leishmania donovani infection

J Antimicrob Chemother. 2012 Aug;67(8):1905-14. doi: 10.1093/jac/dks159. Epub 2012 May 15.

Abstract

Objectives: The aim of the present study was to characterize glycyrrhizic acid (GA) and assess its immunomodulatory potential in a model of experimental visceral leishmaniasis.

Methods: The antileishmanial activity of GA was tested in an amastigote-macrophage model and its non-cytotoxic dose was measured by a cell viability assay. To understand the effector mechanism of GA-treated macrophages against leishmanial parasites, real-time PCR analysis of inducible nitric oxide synthase 2 (iNOS2) was carried out followed by measurement of nitric oxide generation by Griess reagent. The effect of GA on the production of cytokines, such as interleukin (IL)-12, tumour necrosis factor (TNF)-α, IL-10 and transforming growth factor (TGF)-β, was measured by ELISA (protein) and real-time PCR. The expression of iNOS2 and cyclooxygenase-2 (Cox-2) was studied by western blotting. The parasite burden of the liver and spleen following GA treatment was determined by the stamp-smear method, and T cell proliferation was assessed via [³H]thymidine uptake, measured by a liquid scintillation counter.

Results: Results showed that GA treatment caused an enhanced expression of iNOS2 along with inhibition of Cox-2 in Leishmania donovani-infected macrophages. GA treatment in infected macrophages enhanced the expression of IL-12 and TNF-α, concomitant with a down-regulation of IL-10 and TGF-β. GA increased macrophage effector responses via inhibition of Cox-2-mediated prostaglandin E2 release in L. donovani-infected macrophages. GA also decreased hepatic and splenic parasite burden and increased T cell proliferation in Leishmania-infected BALB/c mice.

Conclusions: These results provide a mechanistic understanding of GA-mediated protection against leishmanial parasites within the host.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / pharmacology
  • Cyclooxygenase 2 / biosynthesis
  • Cytokines / metabolism
  • Dinoprostone / metabolism
  • Enzyme-Linked Immunosorbent Assay
  • Gene Expression Profiling
  • Glycyrrhizic Acid / administration & dosage*
  • Glycyrrhizic Acid / pharmacology
  • Immunologic Factors / administration & dosage*
  • Immunologic Factors / pharmacology
  • Leishmania donovani / immunology
  • Leishmania donovani / pathogenicity*
  • Leishmaniasis, Visceral / drug therapy*
  • Liver / parasitology
  • Macrophages / drug effects
  • Macrophages / parasitology
  • Mice
  • Mice, Inbred BALB C
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / biosynthesis
  • Real-Time Polymerase Chain Reaction
  • Spleen / parasitology
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • Immunologic Factors
  • Nitric Oxide
  • Glycyrrhizic Acid
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2
  • Dinoprostone